Brought to you by 
Boehringer Ingelheim funds WW development of CNSI Cerestat
23 Sep 2014
Executive Summary
Boehringer Ingelheim and Cambridge NeuroScience Inc. (CNSI) have agreed to jointly develop CNSI's lead compound Cerestat (aptiganel), for stroke and traumatic brain injury (TBI).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Boehringer Ingelheim funds WW development of CNSI Cerestat
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice